{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T11:33:28Z","timestamp":1793705608686,"version":"4.5.1"},"reference-count":193,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,8,1]]},"abstract":"<jats:p>Biologic response modifiers (BRMs) are substances that interact with and modify the host immune system. BRMs that dampen the immune system are used to treat conditions such as juvenile idiopathic arthritis, psoriatic arthritis, or inflammatory bowel disease and often in combination with other immunosuppressive agents, such as methotrexate and corticosteroids. Cytokines that are targeted include tumor necrosis factor \u03b1; interleukins (ILs) 6, 12, and 23; and the receptors for IL-1\u03b1 (IL-1A) and IL-1\u03b2 (IL-1B) as well as other molecules. Although the risk varies with the class of BRM, patients receiving immune-dampening BRMs generally are at increased risk of infection or reactivation with mycobacterial infections (Mycobacterium tuberculosis and nontuberculous mycobacteria), some viral (herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, hepatitis B) and fungal (histoplasmosis, coccidioidomycosis) infections, as well as other opportunistic infections. The use of BRMs warrants careful determination of infectious risk on the basis of history (including exposure, residence, and travel and immunization history) and selected baseline screening test results. Routine immunizations should be given at least 2 weeks (inactivated or subunit vaccines) or 4 weeks (live vaccines) before initiation of BRMs whenever feasible, and inactivated influenza vaccine should be given annually. Inactivated and subunit vaccines should be given when needed while taking BRMs, but live vaccines should be avoided unless under special circumstances in consultation with an infectious diseases specialist. If the patient develops a febrile or serious respiratory illness during BRM therapy, consideration should be given to stopping the BRM while actively searching for and treating possible infectious causes.<\/jats:p>","DOI":"10.1542\/peds.2016-1209","type":"journal-article","created":{"date-parts":[[2016,7,18]],"date-time":"2016-07-18T05:07:45Z","timestamp":1468818465000},"source":"Crossref","is-referenced-by-count":51,"title":["Infectious Complications With the Use of Biologic Response Modifiers in Infants and Children"],"prefix":"10.1542","volume":"138","author":[{"given":"H. Dele","family":"Davies","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"COMMITTEE ON INFECTIOUS DISEASES","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Byington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne A.","family":"Maldonado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth D.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth","family":"Lynfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flor M.","family":"Munoz-Rivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawn L.","family":"Nolt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Christine","family":"Nyquist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mobeen H.","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H.","family":"Sawyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Steinbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina Q.","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theoklis E.","family":"Zaoutis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2016,8,1]]},"reference":[{"issue":"6","key":"2026032611410824100_B1","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.23721","article-title":"American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis.","volume":"59","author":"Saag","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"9","key":"2026032611410824100_B2","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/cid\/cit489","article-title":"Infections in children and adolescents with juvenile idiopathic arthritis and inflammatory bowel disease treated with tumor necrosis factor-\u03b1 inhibitors: systematic review of the literature.","volume":"57","author":"Toussi","year":"2013","journal-title":"Clin Infect Dis"},{"issue":"6","key":"2026032611410824100_B3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1177\/0885066604267854","article-title":"Serious infections associated with anticytokine therapies in the rheumatic diseases.","volume":"19","author":"Giles","year":"2004","journal-title":"J Intensive Care Med"},{"issue":"15","key":"2026032611410824100_B4","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","article-title":"Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.","volume":"345","author":"Keane","year":"2001","journal-title":"N Engl J Med"},{"issue":"2","key":"2026032611410824100_B5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/j.idc.2020.02.011","article-title":"Mycobacterial infections potentiated by biologics","volume":"34","author":"Calabrese","year":"2020","journal-title":"Infect Dis Clin North Am."},{"issue":"1","key":"2026032611410824100_B6","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.rdc.2016.09.005","article-title":"Opportunistic infections in biologic therapy: risk and prevention","volume":"43","author":"Bryant","year":"2017","journal-title":"Rheum Dis Clin North Am."},{"key":"2026032611410824100_B7","unstructured":"National Comprehensive Cancer Network\n          . Guidelines on the Prevention and Treatment of Cancer-related Infections. National Comprehensive Cancer Network; 2025. Accessed February 17, 2026. https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1457"},{"issue":"2","key":"2026032611410824100_B8","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.idc.2020.02.013","article-title":"Infections related to biologics: agents targeting B cells","volume":"34","author":"Leandro","year":"2020","journal-title":"Infect Dis Clin North Am."},{"issue":"7","key":"2026032611410824100_B9","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.3390\/cancers15071989","article-title":"Infectious complications of targeted therapies for solid cancers or leukemias\/lymphomas","volume":"15","author":"Pilmis","year":"2023","journal-title":"Cancers."},{"issue":"2","key":"2026032611410824100_B10","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.idc.2020.02.014","article-title":"Infectious risks associated with biologics targeting Janus kinase-signal transducer and activator of inflammatory diseases","volume":"34","author":"Benamu","year":"2020","journal-title":"Infect Dis Clin North Am."},{"issue":"1","key":"2026032611410824100_B11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.idc.2017.10.004","article-title":"Infections in children on biologics","volume":"32","author":"Danziger-Isakov","year":"2017","journal-title":"Infect Dis Clin North Am."},{"issue":"8","key":"2026032611410824100_B12","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1038\/ajg.2013.138","article-title":"Opportunistic infections with anti-tumor necrosis factor-\u03b1 therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.","volume":"108","author":"Ford","year":"2013","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2026032611410824100_B13","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.cgh.2006.03.002","article-title":"Serious infections and mortality in association with therapies for Crohn\u2019s disease: TREAT registry.","volume":"4","author":"Lichtenstein","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"2","key":"2026032611410824100_B14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.crohns.2009.02.010","article-title":"European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.","volume":"3","author":"Rahier","year":"2009","journal-title":"J Crohn\u2019s Colitis"},{"issue":"10","key":"2026032611410824100_B15","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1136\/gut.2008.175950","article-title":"The European (ECCO) consensus on infection in IBD: what does it change for the clinician?","volume":"58","author":"Rahier","year":"2009","journal-title":"Gut"},{"issue":"4","key":"2026032611410824100_B16","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/gut.2006.114660","article-title":"Opportunistic infections in patients with inflammatory bowel disease: prevention and diagnosis.","volume":"57","author":"Viget","year":"2008","journal-title":"Gut"},{"issue":"4","key":"2026032611410824100_B17","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features.","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"5","key":"2026032611410824100_B18","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/art.37866","article-title":"Brief report: incidence of selected opportunistic infections among children with juvenile idiopathic arthritis.","volume":"65","author":"Beukelman","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2026032611410824100_B19","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1185\/03007995.2010.547575","article-title":"Safety and efficacy of maintenance infliximab therapy for moderate-to-severe Crohn\u2019s disease in children: REACH open-label extension.","volume":"27","author":"Hyams","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"2026032611410824100_B20","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/pch\/17.3.147","article-title":"Biologic response modifiers to decrease inflammation: focus on infection risks.","volume":"17","author":"Le Saux","year":"2012","journal-title":"Paediatr Child Health"},{"issue":"6","key":"2026032611410824100_B21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1097\/MPG.0b013e31824d1438","article-title":"Risk of infection and prevention in pediatric patients with IBD: ESPGHAN IBD Porto Group commentary.","volume":"54","author":"Veereman-Wauters","year":"2012","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"2026032611410824100_B22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/INF.0b013e3182833cbb","article-title":"Infections in children treated with biological agents.","volume":"32","author":"Woerner","year":"2013","journal-title":"Pediatr Infect Dis J"},{"issue":"1","key":"2026032611410824100_B23","first-page":"2","article-title":"Recommended immunization schedules for persons aged 0 through 18 years\u2014United States, 2013.","volume":"62","author":"Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices;","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"2026032611410824100_B24","first-page":"1","article-title":"Recommended immunization schedules for persons aged 0 through 18 years--United States, 2013.","volume":"62","author":"Centers for Disease Control and Prevention, Advisory Committee on Immunization Practices","year":"2013","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2026032611410824100_B25","first-page":"69","article-title":"Immunization in special clinical circumstances","volume-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2012"},{"issue":"6","key":"2026032611410824100_B26","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2014-2983","article-title":"Interferon-\u03b3 release assays for diagnosis of tuberculosis infection and disease in children.","volume":"134","author":"Starke","year":"2014","journal-title":"Pediatrics"},{"key":"2026032611410824100_B27","first-page":"471","article-title":"Listeria monocytogenes infections (listeriosis)","volume-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2012"},{"key":"2026032611410824100_B28","unstructured":"Remicade (infliximab) [package insert]. Horsham, PA: Janssen Biotech; 2013. Available at: www.remicade.com\/shared\/product\/remicade\/prescribing-information.pdf. Accessed October 22, 2014"},{"issue":"4","key":"2026032611410824100_B29","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry.","volume":"68","author":"Horneff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026032611410824100_B30","unstructured":"Humira (adalimunab) [package insert]. North Chicago, IL: AbbVie; 2013. Available at: www.rxabbvie.com\/pdf\/humira.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B31","unstructured":"Simponi (golimumab) [package insert]. Horsham, PA: Jannsen Biotech; 2013. Available at: www.simponiaria.com\/shared\/product\/simponiaria\/prescribing-information.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B32","unstructured":"Cimzia (certolizumab pegol) [package insert]. Smyrna, GA: UCB; 2012. Available at: www.cimzia.com\/assets\/pdf\/Prescribing_Information.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B33","unstructured":"Orencia (abatacept) [package insert]. Princeton, NJ: Bristol Myers Squibb; 2013. Available at: http:\/\/packageinserts.bms.com\/pi\/pi_orencia.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B34","unstructured":"Kineret (anakinra) [package insert]. Stockholm, Sweden: Swedish Orphan Biovitrum AB; 2013. Available at: www.kineretrx.com\/fileadmin\/user_upload\/kineretus\/documents\/Kineret_Full_Prescribing_Information.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B35","unstructured":"Rituxan (rituximab) [package insert]. South San Francisco, CA: Genentech; 2013. Available at: www.gene.com\/download\/pdf\/rituxan_prescribing.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B36","unstructured":"Actemra (tocilizumab) [package insert]. South San Francisco, CA: Genentech; 2013. Available at: www.gene.com\/download\/pdf\/actemra_prescribing.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B37","unstructured":"Stelara (ustekinumab) [package insert]. Horsham, PA: Janssen Biotech; 2013. Available at: www.stelarainfo.com\/pdf\/PrescribingInformation.pdf. Accessed October 22, 2014"},{"issue":"9","key":"2026032611410824100_B38","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis.","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"key":"2026032611410824100_B39","unstructured":"Ilaris (canakinumab) [package insert]. East Hanover, NJ: Novartis; 2013. Available at: www.pharma.us.novartis.com\/product\/pi\/pdf\/ilaris.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B40","unstructured":"Tysabri (natalizumab) [package insert]. Cambridge, MA: Biogen Idec; 2013. Available at: www.tysabri.com\/pdfs\/I61061-13_PI.pdf. Accessed October 22, 2014"},{"key":"2026032611410824100_B41","unstructured":"Benlysta (belimumab) [package insert]. GlaxoSmithKline, Mississauga, Ontatrio, Canada; 2014. Available at: www.gsksource.com\/gskprm\/en\/US\/adirect\/gskprm?cmd=ProductDetailPage&product_id=1300455676143&featureKey=602522&tab=tab1&footer=yes&pTab=one#nlmhighlights. Accessed October 22, 2014"},{"key":"2026032611410824100_B42","unstructured":"Arcalyst (rilonacept) [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals; 2013. Available at: www.arcalyst.com\/images\/pdf\/ARCALYST-fpi.pdf?phpMyAdmin=e99e09ae33c1fdbbafd69c8883f97963. Accessed October 22, 2014"},{"key":"2026032611410824100_B43","unstructured":"Xeljanz (tofacitinib) [package insert]. New York, NY: Pfizer; 2014. Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=959. Accessed October 22, 2014"},{"key":"2026032611410824100_B44","first-page":"S83","article-title":"The safety of infliximab (Remicade(R)) infusion in clinical practice","author":"Bray","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2026032611410824100_B45","volume-title":"Gastroenterology","author":"Hyams","year":"2012"},{"issue":"22","key":"2026032611410824100_B46","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1056\/NEJM200011303432202","article-title":"Infliximab and methotrexate in the treatment of rheumatoid arthritis.","volume":"343","author":"Lipsky","year":"2000","journal-title":"N Engl J Med"},{"key":"2026032611410824100_B47","first-page":"S572","article-title":"Safety and efficacy of adalimumab (D2E7), a fully human anti-TNF-alpha monoclonal antibody, given in combination with standard antirheumatic therapy: safety trial of adalimumab in rheumatoid arthritis (RA)","volume":"46","author":"Furst","year":"2002","journal-title":"Arthritis Rheum"},{"key":"2026032611410824100_B48","first-page":"S205","article-title":"Adalimumab (D2E7), a fully human anti-TNF-alpha monoclonal antibody, inhibits the progression of structural joint damage in patients with active RA despite concomitant methotrexate therapy","volume":"46","author":"Keystone","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2026032611410824100_B49","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"2026032611410824100_B50","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03009742.2010.517546","article-title":"Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis.","volume":"40","author":"Trachana","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"2","key":"2026032611410824100_B51","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1002\/acr.21788","article-title":"Comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-tumor necrosis factor antibody, in phase III clinical trials.","volume":"65","author":"Hsia","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"2026032611410824100_B52","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","article-title":"Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases.","volume":"90","author":"P\u00e9rez-Alvarez","year":"2011","journal-title":"Medicine (Baltimore)"},{"issue":"Suppl 2","key":"2026032611410824100_B53","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.cmi.2017.12.025","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an ID Perspective (soluble immune effector molecules [I]: antiTNF alpha agents)","volume":"24","author":"Baddley","year":"2018","journal-title":"Clin Microbiol Infect."},{"issue":"9","key":"2026032611410824100_B54","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis.","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026032611410824100_B55","unstructured":"Enbrel (etanercept) [package insert]. Thousand Oaks, CA: Immunex; 2013. Available at: http:\/\/pi.amgen.com\/united_states\/enbrel\/derm\/enbrel_pi.pdf. Accessed October 22, 2014"},{"issue":"4","key":"2026032611410824100_B56","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.idc.2011.08.002","article-title":"Biologics and infections: lessons from tumor necrosis factor blocking agents.","volume":"25","author":"Wallis","year":"2011","journal-title":"Infect Dis Clin North Am"},{"issue":"Suppl 2","key":"2026032611410824100_B57","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1016\/j.cmi.2018.02.002","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (soluble immune effector molecules [II]: agents targeting interleukins, immunoglobulins and complement factors)","volume":"24","author":"Winthrop","year":"2018","journal-title":"Clin Microbiol Infect."},{"issue":"Suppl 2","key":"2026032611410824100_B58","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1016\/j.cmi.2018.02.003","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (agents targeting lymphoid cells surface antigens [I]: CD19, CD20 and CD52)","volume":"24","author":"Mikulska","year":"2018","journal-title":"Clin Microbiol Infect."},{"issue":"2","key":"2026032611410824100_B59","first-page":"152","article-title":"Systematic review of adverse events of IL-1 and IL-6 inhibitor use in pediatrics","volume":"30","author":"Perera","year":"2025","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"5","key":"2026032611410824100_B60","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1016\/j.ard.2025.01.032","article-title":"Expert consensus statement on the treatment of immune-mediated inflammatory diseases with JAKi: 2024 update","volume":"84","author":"Nash","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2026032611410824100_B61","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1759720X12470753","article-title":"The kinase inhibitor tofacitinib in patients with rheumatoid arthritis: latest findings and clinical potential.","volume":"5","author":"Cutolo","year":"2013","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"4","key":"2026032611410824100_B62","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/ni.1701","article-title":"Selectivity and therapeutic inhibition of kinases: to be or not to be?","volume":"10","author":"Ghoreschi","year":"2009","journal-title":"Nat Immunol"},{"issue":"1","key":"2026032611410824100_B63","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1600-065X.2008.00754.x","article-title":"Janus kinases in immune cell signaling.","volume":"228","author":"Ghoreschi","year":"2009","journal-title":"Immunol Rev"},{"issue":"4","key":"2026032611410824100_B64","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.berh.2010.02.003","article-title":"Inhibition of JAK kinases in patients with rheumatoid arthritis: scientific rationale and clinical outcomes.","volume":"24","author":"Riese","year":"2010","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"3","key":"2026032611410824100_B65","doi-asserted-by":"crossref","first-page":"1128\/cmr.00035","DOI":"10.1128\/CMR.00035-19","article-title":"Infectious complications of biological and small molecule targeted immunomodulatory therapies","volume":"33","author":"Davis","year":"2020","journal-title":"Clin Microbiol Rev."},{"key":"2026032611410824100_B66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jpeds.2018.08.065","article-title":"Risk of serious infections associated with biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analyses","volume":"204","author":"Aeschlimann","year":"2019","journal-title":"J Pediatr."},{"issue":"19","key":"2026032611410824100_B67","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.","volume":"295","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"issue":"6","key":"2026032611410824100_B68","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/art.30310","article-title":"Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.","volume":"63","author":"Thompson","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2026032611410824100_B69","first-page":"CD008794","article-title":"Adverse effects of biologics: a network meta-analysis and Cochrane overview.","author":"Singh","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2026032611410824100_B70","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1002\/art.10529","article-title":"Predictors of infection in rheumatoid arthritis.","volume":"46","author":"Doran","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2026032611410824100_B71","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/art.1780340805","article-title":"Methotrexate versus azathioprine in the treatment of rheumatoid arthritis: a forty-eight-week randomized, double-blind trial.","volume":"34","author":"Jeurissen","year":"1991","journal-title":"Arthritis Rheum"},{"key":"2026032611410824100_B72","volume-title":"Enbrel: serious and opportunistic infection rates","year":"2013"},{"issue":"8","key":"2026032611410824100_B73","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1002\/art.34458","article-title":"Rates of hospitalized bacterial infection associated with juvenile idiopathic arthritis and its treatment.","volume":"64","author":"Beukelman","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2026032611410824100_B74","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3899\/jrheum.111555","article-title":"Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age.","volume":"39","author":"Bracaglia","year":"2012","journal-title":"J Rheumatol"},{"issue":"8","key":"2026032611410824100_B75","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients.","volume":"67","author":"Gerloni","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"2026032611410824100_B76","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis.","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"2026032611410824100_B77","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial.","volume":"48","author":"Lovell","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2026032611410824100_B78","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis.","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2026032611410824100_B79","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis.","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2026032611410824100_B80","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2026032611410824100_B81","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.cgh.2011.11.026","article-title":"Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis.","volume":"10","author":"Hyams","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"2026032611410824100_B82","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","article-title":"Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension.","volume":"69","author":"Ruperto","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"2026032611410824100_B83","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/j.1572-0241.2003.07161.x","article-title":"Safety and steroid-sparing experience using infliximab for Crohn\u2019s disease at a pediatric inflammatory bowel disease center.","volume":"98","author":"Stephens","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"2026032611410824100_B84","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MPG.0b013e3181c2c10d","article-title":"Disseminated histoplasmosis and pneumocystis pneumonia in a child with Crohn disease receiving infliximab.","volume":"51","author":"Tschudy","year":"2010","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"12","key":"2026032611410824100_B85","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s10067-012-2082-5","article-title":"Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.","volume":"31","author":"Imagawa","year":"2012","journal-title":"Clin Rheumatol"},{"issue":"Suppl 2","key":"2026032611410824100_B86","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/j.cmi.2018.01.030","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphate receptor modulators and proteasome inhibitors)","volume":"24","author":"Redelman-Sidi","year":"2018","journal-title":"Clin Microbiol Infect."},{"issue":"2","key":"2026032611410824100_B87","first-page":"S52","article-title":"ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus document on the safety of targeted and biological therapies: an infectious diseases perspective (Intracellular signaling pathways: tyrosine kinase and mTOR inhibitors","volume":"24","author":"Reinwald","year":"2018","journal-title":"Clin Microbiol Infect."},{"issue":"6","key":"2026032611410824100_B88","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.1365-2141.2003.04385.x","article-title":"Delayed-onset neutropenia associated with rituximab therapy.","volume":"121","author":"Chaiwatanatorn","year":"2003","journal-title":"Br J Haematol"},{"issue":"3","key":"2026032611410824100_B89","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood-2004-08-3198","article-title":"B-cell recovery following rituximab-based therapy is associated with perturbations in stromal derived factor-1 and granulocyte homeostasis.","volume":"106","author":"Dunleavy","year":"2005","journal-title":"Blood"},{"issue":"3","key":"2026032611410824100_B90","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1532\/IJH97.05105","article-title":"Late-onset neutropenia in patients treated with rituximab for non-Hodgkin\u2019s lymphoma.","volume":"84","author":"Fukuno","year":"2006","journal-title":"Int J Hematol"},{"issue":"5-6","key":"2026032611410824100_B91","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4414\/smw.2004.10458","article-title":"Delayed-onset and long-lasting severe neutropenia due to rituximab.","volume":"134","author":"Hofer","year":"2004","journal-title":"Swiss Med Wkly"},{"issue":"9","key":"2026032611410824100_B92","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1097\/01.tp.0000184275.81396.45","article-title":"Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation.","volume":"80","author":"Mitsuhata","year":"2005","journal-title":"Transplantation"},{"issue":"2","key":"2026032611410824100_B93","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1093\/annonc\/mdl393","article-title":"A high incidence of late-onset neutropenia following rituximab-containing chemotherapy as a primary treatment of CD20-positive B-cell lymphoma: a single-institution study.","volume":"18","author":"Nitta","year":"2007","journal-title":"Ann Oncol"},{"issue":"2","key":"2026032611410824100_B94","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.3324\/haematol.11031","article-title":"Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery.","volume":"92","author":"Terrier","year":"2007","journal-title":"Haematologica"},{"issue":"26","key":"2026032611410824100_B95","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1056\/NEJM200306263482620","article-title":"Neutropenia in patients treated with rituximab.","volume":"348","author":"Voog","year":"2003","journal-title":"N Engl J Med"},{"issue":"11","key":"2026032611410824100_B96","doi-asserted-by":"crossref","first-page":"CS133","DOI":"10.12659\/MSM.882034","article-title":"Rituximab associated neutropenia: description of three cases and an insight into the underlying pathogenesis.","volume":"17","author":"Weissmann-Brenner","year":"2011","journal-title":"Med Sci Monit"},{"issue":"9","key":"2026032611410824100_B97","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis.","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"6","key":"2026032611410824100_B98","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/1074-7613(95)90001-2","article-title":"Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.","volume":"2","author":"Flynn","year":"1995","journal-title":"Immunity"},{"issue":"1","key":"2026032611410824100_B99","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0002-9343(01)01035-X","article-title":"Exacerbation of Mycobacterium tuberculosis enteritis masquerading as Crohn\u2019s disease after treatment with a tumor necrosis factor-alpha inhibitor.","volume":"112","author":"Wagner","year":"2002","journal-title":"Am J Med"},{"issue":"5","key":"2026032611410824100_B100","doi-asserted-by":"crossref","first-page":"e1000778","DOI":"10.1371\/journal.pcbi.1000778","article-title":"Identification of key processes that control tumor necrosis factor availability in a tuberculosis granuloma.","volume":"6","author":"Fallahi-Sichani","year":"2010","journal-title":"PLOS Comput Biol"},{"issue":"4","key":"2026032611410824100_B101","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1016\/j.jtbi.2010.05.012","article-title":"TNF and IL-10 are major factors in modulation of the phagocytic cell environment in lung and lymph node in tuberculosis: a next-generation two-compartmental model.","volume":"265","author":"Marino","year":"2010","journal-title":"J Theor Biol"},{"issue":"6","key":"2026032611410824100_B102","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/mt.2008.69","article-title":"Therapeutic effect of recombinant adenovirus encoding interferon-gamma in a murine model of progressive pulmonary tuberculosis.","volume":"16","author":"Mata-Espinosa","year":"2008","journal-title":"Mol Ther"},{"issue":"3","key":"2026032611410824100_B103","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1586\/eci.11.6","article-title":"The risk of tuberculosis in patients treated with TNF antagonists.","volume":"7","author":"Salgado","year":"2011","journal-title":"Expert Rev Clin Immunol"},{"issue":"3","key":"2026032611410824100_B104","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1086\/421494","article-title":"Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.","volume":"39","author":"Mohan","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2026032611410824100_B105","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/ard.2009.118935","article-title":"Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR).","volume":"69","author":"Dixon","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026032611410824100_B106","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1186\/ar995","article-title":"Does safety make a difference in selecting the right TNF antagonist?","volume":"6","author":"Fleischmann","year":"2004","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"2026032611410824100_B107","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1001\/jama.282.7.677","article-title":"Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country","volume":"282","author":"Dye","year":"1999","journal-title":"JAMA"},{"issue":"8","key":"2026032611410824100_B108","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.","volume":"54","author":"Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"7","key":"2026032611410824100_B109","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1002\/art.24632","article-title":"Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies Registry","volume":"60","author":"Tubach","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2026032611410824100_B110","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00002281-200405000-00006","article-title":"Long-term risks associated with biologic response modifiers used in rheumatic diseases.","volume":"16","author":"Imperato","year":"2004","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"2026032611410824100_B111","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection.","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"8","key":"2026032611410824100_B112","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1056\/NEJM200202213460815","article-title":"Tuberculosis and treatment with infliximab.","volume":"346","author":"Myers","year":"2002","journal-title":"N Engl J Med"},{"issue":"4","key":"2026032611410824100_B113","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/rheumatology\/keh074","article-title":"Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritis.","volume":"43","author":"Armbrust","year":"2004","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2026032611410824100_B114","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1002\/art.21137","article-title":"Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.","volume":"52","author":"Askling","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2026032611410824100_B115","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s10067-009-1334-5","article-title":"Preventing tuberculosis in children receiving anti-TNF treatment.","volume":"29","author":"Ayaz","year":"2010","journal-title":"Clin Rheumatol"},{"issue":"10","key":"2026032611410824100_B116","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1038\/ncprheum0621","article-title":"Nontuberuclous mycobacterial disease: updated diagnostic criteria for an under-recognized infectious complication of anti-tumor necrosis factor therapy.","volume":"3","author":"Winthrop","year":"2007","journal-title":"Nat Clin Pract Rheumatol"},{"issue":"11","key":"2026032611410824100_B117","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1086\/587989","article-title":"Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.","volume":"46","author":"Winthrop","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2026032611410824100_B118","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.3201\/eid1510.090310","article-title":"Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.","volume":"15","author":"Winthrop","year":"2009","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"2026032611410824100_B119","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1002\/ibd.22950","article-title":"Varicella zoster virus infection in inflammatory bowel disease.","volume":"18","author":"Cullen","year":"2012","journal-title":"Inflamm Bowel Dis"},{"issue":"7","key":"2026032611410824100_B120","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2009.146","article-title":"Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents.","volume":"301","author":"Strangfeld","year":"2009","journal-title":"JAMA"},{"issue":"8","key":"2026032611410824100_B121","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/art.23112","article-title":"The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom.","volume":"57","author":"Smitten","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2026032611410824100_B122","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/annrheumdis-2011-201108","article-title":"Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.","volume":"72","author":"Galloway","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"2026032611410824100_B123","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1001\/jama.2013.1099","article-title":"Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster.","volume":"309","author":"Winthrop","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"2026032611410824100_B124","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1093\/rheumatology\/kel328","article-title":"Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders.","volume":"45","author":"Wolfe","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"2026032611410824100_B125","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1086\/605498","article-title":"Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors.","volume":"49","author":"Bradford","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2026032611410824100_B126","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1186\/1752-1947-2-282","article-title":"Disseminated cutaneous herpes simplex virus-1 in a woman with rheumatoid arthritis receiving infliximab: a case report.","volume":"2","author":"Justice","year":"2008","journal-title":"J Med Case Reports"},{"issue":"4","key":"2026032611410824100_B127","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1136\/ard.2010.137422","article-title":"Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.","volume":"70","author":"Salmon-Ceron","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"2026032611410824100_B128","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/j.1440-1746.2011.06622.x","article-title":"Education and imaging: gastrointestinal: herpes simplex virus-associated erythema multiforme (HAEM) during infliximab treatment for ulcerative colitis.","volume":"26","author":"Sciaudone","year":"2011","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"2026032611410824100_B129","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s00134-003-1867-z","article-title":"Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate.","volume":"29","author":"van der Klooster","year":"2003","journal-title":"Intensive Care Med"},{"issue":"9","key":"2026032611410824100_B130","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/MEG.0b013e32831de271","article-title":"Successful prophylaxis with valaciclovir for relapsing HSV-1 in a girl treated with infliximab for moderate Crohn\u2019s disease.","volume":"21","author":"Checchin","year":"2009","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"4","key":"2026032611410824100_B131","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1517\/14712598.2011.554810","article-title":"The impact of biologic response modifiers on hepatitis B virus infection.","volume":"11","author":"Carroll","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"7","key":"2026032611410824100_B132","doi-asserted-by":"crossref","first-page":"387","DOI":"10.4254\/wjh.v5.i7.387","article-title":"Hepatitis B virus reactivation in hepatitis B virus surface antigen negative patients receiving immunosuppression: a hidden threat.","volume":"5","author":"Zachou","year":"2013","journal-title":"World J Hepatol"},{"issue":"1","key":"2026032611410824100_B133","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.jaad.2013.08.049","article-title":"From the Medical Board of the National Psoriasis Foundation: recommendations for screening for hepatitis B infection prior to initiating anti-tumor necrosis factor-alfa inhibitors or other immunosuppressive agents in patients with psoriasis.","volume":"70","author":"Motaparthi","year":"2014","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"2026032611410824100_B134","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0025-6196(11)60839-2","article-title":"Fungal infections complicating tumor necrosis factor alpha blockade therapy.","volume":"83","author":"Tsiodras","year":"2008","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"2026032611410824100_B135","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ccm.2009.02.004","article-title":"Coccidioidomycosis: a review of recent advances.","volume":"30","author":"Ampel","year":"2009","journal-title":"Clin Chest Med"},{"issue":"6","key":"2026032611410824100_B136","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/art.20454","article-title":"Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.","volume":"50","author":"Bergstrom","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"12","key":"2026032611410824100_B137","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/acr.21784","article-title":"Management of coccidioidomycosis in patients receiving biologic response modifiers or disease-modifying antirheumatic drugs.","volume":"64","author":"Taroumian","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"2026032611410824100_B138","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1086\/648724","article-title":"Recognition, diagnosis, and treatment of histoplasmosis complicating tumor necrosis factor blocker therapy.","volume":"50","author":"Hage","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2026032611410824100_B139","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/nrrheum.2009.105","article-title":"Preventing and treating biologic-associated opportunistic infections.","volume":"5","author":"Winthrop","year":"2009","journal-title":"Nat Rev Rheumatol"},{"issue":"10","key":"2026032611410824100_B140","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"2","key":"2026032611410824100_B141","doi-asserted-by":"crossref","first-page":":389","DOI":"10.1016\/j.idc.2020.02.010","article-title":"Fungal infections potentiated by biologics","volume":"34","author":"Davis","year":"2020","journal-title":"Infect Dis Clin North Am."},{"issue":"9","key":"2026032611410824100_B142","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s10096-013-1873-1","article-title":"Listeriosis in patients receiving biologic therapies.","volume":"32","author":"Bodro","year":"2013","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"5","key":"2026032611410824100_B143","first-page":"854","article-title":"Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: the Spanish Study Group experience.","volume":"26","author":"Pe\u00f1a-Sagredo","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"2026032611410824100_B144","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2026032611410824100_B145","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1378\/chest.12-2820","article-title":"Incidence and risk factors of Legionella pneumophila pneumonia during anti-tumor necrosis factor therapy: a prospective French study.","volume":"144","author":"Lanternier","year":"2013","journal-title":"Chest"},{"issue":"10","key":"2026032611410824100_B146","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.1086\/508538","article-title":"Emergence of Legionella pneumophila pneumonia in patients receiving tumor necrosis factor-alpha antagonists.","volume":"43","author":"Tubach","year":"2006","journal-title":"Clin Infect Dis"},{"issue":"9","key":"2026032611410824100_B147","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1093\/rheumatology\/keh696","article-title":"Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis.","volume":"44","author":"Torre-Cisneros","year":"2005","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"2026032611410824100_B148","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1002\/art.22783","article-title":"Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase Epstein-Barr virus load in patients with rheumatoid arthritis.","volume":"57","author":"Balandraud","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2026032611410824100_B149","doi-asserted-by":"crossref","first-page":"208","DOI":"10.3109\/03009742.2011.630328","article-title":"High prevalence of Pneumocystis jirovecii colonization among patients with autoimmune inflammatory diseases and corticosteroid therapy.","volume":"41","author":"Fritzsche","year":"2012","journal-title":"Scand J Rheumatol"},{"issue":"3","key":"2026032611410824100_B150","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1093\/rheumatology\/keq314","article-title":"Pneumocystis jirovecii colonization in patients with systemic autoimmune diseases: prevalence, risk factors of colonization and outcome.","volume":"50","author":"Mekinian","year":"2011","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"2026032611410824100_B151","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.3899\/jrheum.091294","article-title":"A cluster of Pneumocystis jirovecii infection among outpatients with rheumatoid arthritis.","volume":"37","author":"Mori","year":"2010","journal-title":"J Rheumatol"},{"issue":"10","key":"2026032611410824100_B152","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.4049\/jimmunol.176.10.6147","article-title":"B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection.","volume":"176","author":"Lund","year":"2006","journal-title":"J Immunol"},{"issue":"1","key":"2026032611410824100_B153","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1378\/chest.12-0477","article-title":"Pneumocystis pneumonia in patients treated with rituximab.","volume":"144","author":"Martin-Garrido","year":"2013","journal-title":"Chest"},{"issue":"8","key":"2026032611410824100_B154","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.3899\/jrheum.081270","article-title":"A followup study of asymptomatic carriers of Pneumocystis jiroveci during immunosuppressive therapy for rheumatoid arthritis.","volume":"36","author":"Mori","year":"2009","journal-title":"J Rheumatol"},{"key":"2026032611410824100_B155","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.3949\/ccjm.79.s3.11","article-title":"Biologic agents in the treatment of granulomatosis with polyangiitis.","volume":"79","author":"Specks","year":"2012","journal-title":"Cleve Clin J Med"},{"issue":"11","key":"2026032611410824100_B156","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1007\/s10067-013-2293-4","article-title":"Should Pneumocystis jiroveci prophylaxis be recommended with rituximab treatment in ANCA-associated vasculitis?","volume":"32","author":"Besada","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"9","key":"2026032611410824100_B157","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.4065\/82.9.1052","article-title":"Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials.","volume":"82","author":"Green","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"6","key":"2026032611410824100_B158","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s10620-006-9250-x","article-title":"Pneumocystis jiroveci (carinii) pneumonia after infliximab therapy: a review of 84 cases.","volume":"52","author":"Kaur","year":"2007","journal-title":"Dig Dis Sci"},{"issue":"6","key":"2026032611410824100_B159","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/s10165-012-0615-z","article-title":"Pneumocystis jirovecii pneumonia associated with etanercept treatment in patients with rheumatoid arthritis: a retrospective review of 15 cases and analysis of risk factors.","volume":"22","author":"Tanaka","year":"2012","journal-title":"Mod Rheumatol"},{"issue":"6","key":"2026032611410824100_B160","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3109\/s10165-012-0796-5","article-title":"Clinical characteristics and risk factors for Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving adalimumab: a retrospective review and case-control study of 17 patients.","volume":"23","author":"Watanabe","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"3","key":"2026032611410824100_B161","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/cid\/cit816","article-title":"2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.","volume":"58","author":"Rubin","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"2026032611410824100_B162","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/art.42386","article-title":"2022 American College of Rheumatology Guideline for vaccinations in patients with rheumatic and musculoskeletal diseases","volume":"75","author":"Bass","year":"2023","journal-title":"Arthritis Rheumatol."},{"issue":"19","key":"2026032611410824100_B163","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1016\/j.vaccine.2022.03.041","article-title":"Efficacy, immunogenicity, and safety of available vaccines in children on biologics: a systematic review and meta-analysis","volume":"40","author":"Gertioso","year":"2022","journal-title":"Vaccine."},{"key":"2026032611410824100_B164","first-page":"39","article-title":"Testing for Mycobacterium tuberculosis infection","volume-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2012"},{"issue":"6","key":"2026032611410824100_B165","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.semarthrit.2008.12.002","article-title":"The effect of infliximab and timing of vaccination on the humoral response to influenza vaccination in patients with rheumatoid arthritis and ankylosing spondylitis.","volume":"39","author":"Elkayam","year":"2010","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"2026032611410824100_B166","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1086\/587063","article-title":"Vaccination in patients with chronic rheumatic or autoimmune diseases.","volume":"46","author":"Gl\u00fcck","year":"2008","journal-title":"Clin Infect Dis"},{"issue":"1","key":"2026032611410824100_B167","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/ajg.2011.295","article-title":"Hepatitis B immunity and response to booster vaccination in children with inflammatory bowel disease treated with infliximab.","volume":"107","author":"Moses","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"2026032611410824100_B168","first-page":"952","article-title":"Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone.","volume":"34","author":"Visvanathan","year":"2007","journal-title":"J Rheumatol"},{"issue":"1","key":"2026032611410824100_B169","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/art.25034","article-title":"Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial.","volume":"62","author":"Bingham","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2026032611410824100_B170","doi-asserted-by":"crossref","first-page":"R171","DOI":"10.1186\/ar4358","article-title":"Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis.","volume":"15","author":"Crnkic Kapetanovic","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"11","key":"2026032611410824100_B171","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia.","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"2026032611410824100_B172","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/art.25033","article-title":"Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab.","volume":"62","author":"van Assen","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"6","key":"2026032611410824100_B173","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/blood.V100.6.2257","article-title":"Rituximab treatment results in impaired secondary humoral immune responsiveness.","volume":"100","author":"van der Kolk","year":"2002","journal-title":"Blood"},{"key":"2026032611410824100_B174","unstructured":"Centers for Disease Control and Prevention\n          . Latent tuberculosis infection: a guide for primary health care providers. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Available at: www.cdc.gov\/tb\/publications\/ltbi\/diagnosis.htm. Accessed October 22, 2014"},{"key":"2026032611410824100_B175","unstructured":"Centers for Disease Control and Prevention\n          . TB guidelines, treatment. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Available at: www.cdc.gov\/tb\/publications\/guidelines\/treatment.htm. Accessed October 22, 2014"},{"key":"2026032611410824100_B176","first-page":"1","article-title":"Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection\u2014United States, 2010.","volume":"59","author":"Mazurek","year":"2010","journal-title":"MMWR Recomm Rep"},{"key":"2026032611410824100_B177","first-page":"736","article-title":"Tuberculosis","volume-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2012"},{"issue":"10","key":"2026032611410824100_B178","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1097\/01.inf.0000141738.60845.da","article-title":"A large histoplasmosis outbreak among high school students in Indiana, 2001.","volume":"23","author":"Chamany","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"2026032611410824100_B179","unstructured":"National Institute for Occupational Safety and Health\n          . Histoplasmosis, protecting workers at risk. Atlanta, GA: National Institute for Occupational Safety and Health, Department of Health and Human Services; 2004. Available at: www.cdc.gov\/niosh\/docs\/2005-109\/. Accessed October 22, 2014"},{"issue":"8","key":"2026032611410824100_B180","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/RHU.0b013e3181c0696e","article-title":"The risk of infections with tumor necrosis factor-alpha inhibitors.","volume":"15","author":"Jassal","year":"2009","journal-title":"J Clin Rheumatol"},{"issue":"1","key":"2026032611410824100_B181","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0891-5520(02)00040-5","article-title":"Coccidioidomycosis.","volume":"17","author":"Chiller","year":"2003","journal-title":"Infect Dis Clin North Am"},{"issue":"3","key":"2026032611410824100_B182","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1097\/01.md.0000126762.91040.fd","article-title":"Coccidioidomycosis: a descriptive survey of a reemerging disease\u2014clinical characteristics and current controversies.","volume":"83","author":"Crum","year":"2004","journal-title":"Medicine (Baltimore)"},{"issue":"5","key":"2026032611410824100_B183","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1086\/319203","article-title":"Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995-1996.","volume":"32","author":"Rosenstein","year":"2001","journal-title":"Clin Infect Dis"},{"key":"2026032611410824100_B184","first-page":"774","article-title":"Varicella-zoster infections","volume-title":"Red Book: 2012 Report of the Committee on Infectious Diseases","author":"American Academy of Pediatrics","year":"2012"},{"key":"2026032611410824100_B185","unstructured":"Centers for Disease Control and Prevention\n          . Hepatitis B information for health professionals. Atlanta, GA: Centers for Disease Control and Prevention; 2013. Available at: www.cdc.gov\/hepatitis\/hbv\/hbvfaq.htm. Accessed October 22, 2014"},{"issue":"3","key":"2026032611410824100_B186","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.semarthrit.2007.10.011","article-title":"Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection.","volume":"38","author":"Carroll","year":"2008","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"2026032611410824100_B187","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.3899\/jrheum.110289","article-title":"Hepatitis B virus reactivation by immunosuppressive therapy in patients with autoimmune diseases: risk analysis in hepatitis B surface antigen-negative cases.","volume":"38","author":"Kato","year":"2011","journal-title":"J Rheumatol"},{"issue":"2","key":"2026032611410824100_B188","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/hep.21513","article-title":"Chronic hepatitis B.","volume":"45","author":"Lok","year":"2007","journal-title":"Hepatology"},{"issue":"2","key":"2026032611410824100_B189","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11908-009-0017-3","article-title":"Reactivation of hepatitis B: pathogenesis and clinical implications.","volume":"11","author":"Post","year":"2009","journal-title":"Curr Infect Dis Rep"},{"issue":"3","key":"2026032611410824100_B190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1>3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.","volume":"62","author":"Yeo","year":"2000","journal-title":"J Med Virol"},{"issue":"2","key":"2026032611410824100_B191","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1002\/hep.21051","article-title":"Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy.","volume":"43","author":"Yeo","year":"2006","journal-title":"Hepatology"},{"issue":"10","key":"2026032611410824100_B192","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","article-title":"Vaccinations in patients with immune-mediated inflammatory diseases.","volume":"49","author":"Rahier","year":"2010","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2026032611410824100_B193","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/practneurol-2011-000092","article-title":"Natalizumab-associated progressive multifocal leucoencephalopathy: a practical approach to risk profiling and monitoring.","volume":"12","author":"Hunt","year":"2012","journal-title":"Pract Neurol"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-1209\/1703379\/peds_20161209.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/doi\/10.1542\/peds.2016-1209\/1703379\/peds_20161209.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T15:41:41Z","timestamp":1774539701000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/138\/2\/e20161209\/52479\/Infectious-Complications-With-the-Use-of-Biologic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,1]]},"references-count":193,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,8,1]]},"published-print":{"date-parts":[[2016,8,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2016-1209","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,1]]},"article-number":"e20161209"}}